SCHEMBL6073545

SCHEMBL6073545

CSc1ncc2cc(F)c(=O)[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
DAO P14920 2/20 0.37
MAPT P10636 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
DDO Q99489 1/20 0.33
AHR P35869 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PDE9A O76083 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
NTRK1 P04629 1/20 0.31
HASPIN Q8TF76 1/20 0.31
MAPK14 Q16539 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
PDE4B Q07343 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262113 0.83 MEN1 (0.39) HPGDMEN1KMT2AMAPTRXFP1
SCHEMBL6073419 0.81 MEN1 (0.43) HPGDMEN1KMT2ADAOMAPT
SCHEMBL29538008 0.81 MEN1 (0.38) MEN1KMT2ADAOMAPTAHR
SCHEMBL661610 0.81 MEN1 (0.38) MEN1KMT2ADAOMAPTAHR
SCHEMBL13345301 0.81 MEN1 (0.38) HPGDMEN1KMT2AMAPTAHR
SCHEMBL31637509 0.81 MEN1 (0.43) HPGDMEN1KMT2ADAOMAPT
SCHEMBL4180912 0.81 MEN1 (0.40) MEN1KMT2AMAPTRXFP1NPC1
SCHEMBL24669277 0.78 HTT (0.38) MEN1KMT2AMAPTAHRALDH1A1
SCHEMBL10323760 0.78 KDM6B (0.50) HPGDMEN1KMT2AAHRALDH1A1
SCHEMBL16152749 0.78 MAPK1 (0.40) HPGDMEN1KMT2AMAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 HPGD 1053/4885MEN1 4797/4885KMT2A 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.